Book Value per Share: Cyclacel (CYCC)

Public company logo of Cyclacel Pharmaceuticals, Inc. (CYCC)

The bps metric reflects the dynamics of net assets per share, with the value currently standing at 2.28. The Cyclacel Pharmaceuticals (CYCC) team brings together leading cancer biologists dedicated to the study of cell cycles. Transparent management effectively allocates the R&D budget. Strong patent positions regarding inhibitors provide a robust defense, although early-stage trials maintain high volatility.

CYCC - Cyclacel Pharmaceuticals, Inc. Book Value of One Share over the range 07/04/2022 - 09/12/2025

Summary analytical data breakdowns for cyclacel.com (CYCC)

- price and consensus price forecast:
Stock Price Cyclacel Pharmaceuticals Inc.|CYCC - Consensus Target
- market capitalization data:
Market Capitalization Cyclacel Pharmaceuticals|CYCC - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share Cyclacel|CYCC - Book Value of Business|Market Capitalization to Book Value Ratio cyclacel.com|CYCC - Company Assets
- debt and liquidity data:
Debt to Equity Cyclacel Pharmaceuticals|CYCC - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Cyclacel|CYCC - Company Cumulative Debt|Debt to Book Capitalization Ratio Cyclacel Pharmaceuticals
Fundamental company valuation:CYCC Cyclacel Pharmaceuticals Inc.
Manufactured product of cyclacel.com

Net asset value per share allows for the elimination of speculative overvaluation by measuring residual capital after all liabilities are settled. For Cyclacel Pharmaceuticals (CYCC), where funding inflows depend on FDA verdicts regarding molecular toxicity, the average book value per share serves as an indicator of financial survival, confirming the biotech's ability to maintain its asset base while ensuring full patient retention in clinical trials.

Competitors of Cyclacel Pharmaceuticals (CYCC)

INCY: Book Value per Share|HCM - Accounting Value per Share|NUVB (Nuvation Bio Inc.) - Book Value per Share|dayonebio.com (DAWN) - Accounting Value per Share|Monopar Therapeutics Inc. - Book Value per Share|Book Value of One Share Inhibrx|I-Mab - Book Value per Share|Net Asset Value per Share FENC (Fennec)|HRTX - Net Assets per Single Share|Equity per Share nuvectis.com NVCT|CHRS (Coherus Biosciences) - Book Value per Share|CRBP: Net Asset Value per Share|Net Assets per Single Share cardiffoncology.com CRDF|BeyondSpring Inc (BYSI) - Accounting Value of a Share|BCAB (BioAtla Inc) - Book Value per Share|Book Value per Share LIXT|Net Assets per Single Share Citius Pharmaceuticals (CTXR)|Net Assets per Single Share Cellectar Biosciences Inc CLRB|Accounting Value per Share BioLineRx Corp|Can-Fite - Accounting Value of a Share|APRE (Aprea) - Net Assets per Single Share|KZIA: Net Asset Value per Share|Net Assets per Single Share silexion.com|NuCana (NCNA) - Equity per Share|Book Value per Share CMRX|Accounting Value per Share GTHX|Kronos Bio, Inc. - Net Assets per Single Share|Net Asset Value per Share KTRA (kintara.com)|Net Assets per Single Share Oncternal Therapeutics, Inc. ONCT|Portage Biotech Inc - Net Assets per Single Share